Почетна › Акутна миелоидна леукемија › Висконсин
Клинички испитувања за Акутна миелоидна леукемија во Висконсин
25 студии за Акутна миелоидна леукемија бараат учесници на локации во Висконсин.
Градови во Висконсин
- Milwaukee17 студии
- Madison16 студии
- Green Bay8 студии
- La Crosse6 студии
- Wausau6 студии
- Stevens Point6 студии
- Sheboygan4 студии
Официјален текст на студијата (англиски)
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
- Gundersen Lutheran Medical Center, La Crosse
Се регрутираФаза 2
Возраст 60 и постари · Сите полови · Ажурирано 5.10.2026 · NCT07437950MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- ThedaCare Regional Cancer Center, Appleton
- Duluth Clinic Ashland, Ashland
- Aurora Cancer Care-Southern Lakes VLCC, Burlington
- и уште 41
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 5.10.2026 · NCT05564390Ivosidenib as Post-HSCT Maintenance for AML
- Froedtert Hospital & the Medical College of Wisconsin, Milwaukee
Се регрутираФаза 2
Возраст од 18 до 75 · Сите полови · Ажурирано 5.10.2026 · NCT06707493Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Aspirus Cancer Care-Antigo-Volm Cancer Center, Antigo
- ThedaCare Regional Cancer Center, Appleton
- ThedaCare Regional Medical Center - Appleton, Appleton
- и уште 50
Се регрутираНабљудувачка студијаДобредојдени се здрави волонтери
Возраст од 40 до 75 · Сите полови · Ажурирано 2.10.2026 · NCT05334069Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Hospital of Wisconsin, Milwaukee
Се регрутираНабљудувачка студија
Возраст од 0 до 38 · Сите полови · Ажурирано 1.10.2026 · NCT06131801Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- ThedaCare Regional Cancer Center, Appleton
- ThedaCare Regional Medical Center - Appleton, Appleton
- Duluth Clinic Ashland, Ashland
- и уште 6
Се регрутираФаза 2
Возраст од 18 до 59 · Сите полови · Ажурирано 28.9.2026 · NCT05554393Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- Duluth Clinic Ashland, Ashland
- Saint Vincent Hospital Cancer Center Green Bay, Green Bay
- Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay
- и уште 9
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT06672146Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- ThedaCare Regional Cancer Center, Appleton
- ThedaCare Regional Medical Center - Appleton, Appleton
- Duluth Clinic Ashland, Ashland
- и уште 8
Се регрутираФаза 2
Возраст од 18 до 59 · Сите полови · Ажурирано 22.9.2026 · NCT05554406Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- ThedaCare Regional Cancer Center, Appleton
- Duluth Clinic Ashland, Ashland
- Saint Vincent Hospital Cancer Center Green Bay, Green Bay
- и уште 11
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT06317649A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Saint Vincent Hospital Cancer Center Green Bay, Green Bay
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
- Marshfield Medical Center-Marshfield, Marshfield
- и уште 1
Се регрутираФаза 3
6 Months – 21 Years · Сите полови · Ажурирано 17.9.2026 · NCT04293562A Study of BGB-11417 in Participants With Myeloid Malignancies
- Medical College of Wisconsin, Milwaukee
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 14.9.2026 · NCT04771130Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
- Saint Vincent Hospital Cancer Center Green Bay, Green Bay
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Се регрутираФаза 3
Возраст од 1 до 25 · Сите полови · Ажурирано 4.9.2026 · NCT07022678The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
- Marshfield Medical Center-Marshfield, Marshfield
Се регрутираФаза 1/2
До возраст 22 · Сите полови · Ажурирано 25.8.2026 · NCT04726241Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Wisconsin, Madison
- Froedtert & Medical College of Wisconsin, Milwaukee
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 20.8.2026 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Froedtert & Medical College Clinics, Milwaukee
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 20.8.2026 · NCT06001788ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
- Medical College of Wisconsin, Milwaukee
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 18.8.2026 · NCT06656494A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of Wisconsin - Madison, Madison
- Children's Hospital of Wisconsin, Milwaukee
Се регрутираНабљудувачка студија
Сите возрасти · Сите полови · Ажурирано 6.7.2026 · NCT01351545SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
- University of Wisconsin Carbone Cancer Center, Madison
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 14.5.2026 · NCT06222580A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Froedtert & Medical College of Wisconsin, Milwaukee
Се регрутираФаза 2/3
Возраст 18 и постари · Сите полови · Ажурирано 30.4.2026 · NCT04256317Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
- University of Wisconsin Carbone Cancer Center, Madison
Се регрутираФаза 1
До возраст 21 · Сите полови · Ажурирано 22.4.2026 · NCT05101551A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- University of Wisconsin Hospital and Clinics, Madison
- Medical College of Wisconsin Cancer Center, Milwaukee
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 13.3.2026 · NCT05735184Venetoclax to Augment Epigenetic Modification and Chemotherapy
- Children's Wisconsin, Milwaukee
Се регрутираФаза 1
Возраст од 1 до 25 · Сите полови · Ажурирано 12.1.2026 · NCT05317403Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- University of Wisconsin Carbone Cancer Center, Madison
Се регрутираФаза 1
7 Months – 21 Years · Сите полови · Ажурирано 16.10.2025 · NCT02508038A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
- University of Wisconsin Clinical Science Center, Madison
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 24.9.2025 · NCT06501196Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
- University of Wisconsin, Madison
Се регрутираДобредојдени се здрави волонтери
Возраст од 18 до 120 · Сите полови · Ажурирано 25.7.2025 · NCT05237258Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.